ArticleClinical case reports2026
Juvenile Generalized Pustular Psoriasis: Management in Children-A Case Series.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile Generalized Pustular Psoriasis (GPP) is an extremely rare and potentially life-threatening inflammatory disease. We report three cases of Juvenile GPP that presented with recurrent episodes of widespread painful erythema with sterile pustules accompanied by fever and malaise. None of the patients had a prior history of plaque-type psoriasis. There are no established guidelines for the management of pustular psoriasis in the pediatric age group. During our treatment, one patient responded well to a low dose of Cyclosporine alone without any recurrence following treatment. However, in the other two patients, an escalation of Cyclosporine dose (≥ 5 mg/kg) was required due to frequent relapses. Additionally, Acitretin 0.2-1 mg/kg was considered for maintenance therapy. However, the commercially available dose of Acitretin in our institution was soft capsules of 25 mg only. Hence, we administered Acitretin 25 mg to our patients on alternate days for maintenance therapy. Patients showed significant improvement in cutaneous lesions, and the frequency of relapses gradually declined. Despite the increasing recommendation of biologic agents, the high cost and unavailability of biologic agents restrict their use in clinical practice. Cyclosporine and Acitretin have remained the main therapeutic strategies in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.